奥扎格雷钠联合氯比格雷对非ST段抬高型急性冠脉综合征患者血清hs-CRP,MMP-9和sCD40L的影响

The effectiveness of sodium ozagrel plus clopidogrel on the hs-CRP,MMP-9 and sCD40L in the serum of patients with non-ST-segment elevation acute coronary syndrome

目的探讨奥扎格雷钠联合氯比格雷对非ST段抬高型急性冠脉综合征患者血清超敏C反应蛋白(hs-CRP),金属蛋白酶9(MMP-9)和可溶性CD40配体(sCD40L)的影响。方法 82例非ST段抬高型的急性冠脉综合征患者随机分为两组,对照组40例,采用常规治疗,治疗组42例,采用常规治疗加用奥扎格雷钠和氯比格雷,两组共治疗14 d。测定两组患者治疗前后血清的hs-CRP.MMP-9和sCD40L的表达。结果两组治疗后均明显降低血清hs-CRP,MMP-9和sCD40L的表达,并且治疗组改善hs-CRP,MMP-9和sCD40L的表达均明显优于对照组(P<0.05)。结论奥扎格雷钠联合氯比格雷可以明显减少非ST段抬高型急性冠脉综合征患者血清hs-CRP,MMP-9和sCD40L的表达,从而可以改善病情。

Objective To study the effectiveness of sodium ozagrel plus clopidogrel on the high sensi- tivity C-reactive protein（ hs-CRP）, met alloproteinase-9 （MMP-9） and soluble CIM0 ligand（sCD40L） in the se- rum of patients with non-ST-segment elevation acute coronary syndrome. Methods Eighty-two patients with non-ST-segment elevation acute coronary syndrome were randomly divided into two groups, the control group （n = 40 cases） and the treatment group （n = 42 cases）. The patients in the control group were treated through the conventional treatment and the patients in the treatment group were treated through sodium ozagrel plus clopi- dogrel except the conventional treatment. They were treated for forteen days. The hs-CRP, MMP-9 and sCIMOL in the serum were detected before and after treatment. Results The hs-CRP, MMP-9 and sCIMOL in the serum were all lowed after treatment in both groups. The hs-CRP, MMP-9 and sCD40L in the treatment were improved significantly more than those of the control group（P 〈0. 05）. Conclusion Sodium ozagrel plus clopidogrel can significantly decrease the hs-CRP, MMP-9 and sCIMOL in the serum of patients with non-ST-segment elevation acute coronary syndrome.